PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the TNM staging system, they form a heterogeneous group, which is reflected in the survival outcome. The increasing amount of information for an individual patient and the growing number of treatment options facilitate personalized treatment, but they also complicate treatment decision making. Decision support systems (DSS), which provide individualized prognostic information, can overcome this but are currently lacking. A DSS for stage III NSCLC requires the development and integration..
BACKGROUND: Individually tailored cancer treatment is essential to ensure optimal treatment and reso...
Abstract Background The current TNM staging system is far from perfect in predicting the survival of...
OBJECTIVE:Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is h...
PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
PurposeAlthough patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according...
Importance: Nomogram prognostic models can facilitate cancer patient treatment plans and patient enr...
The 1997 International staging system (ISS) classification separated stage III non-small cell lung c...
Purpose: Tools for survival prediction for non-small cell lung cancer (NSCLC) patients treated with ...
We sought to develop and validate a clinical nomogram model for predicting overall survival (OS) in ...
IntroductionAccurate prognosis assessment after non–small-cell lung cancer (NSCLC) diagnosis is an e...
Objective Surgery is the first choice of treatment for localised non small cell lung cancer (NSCLC) ...
Background: A clinical decision support system (CDSS) has been designed to predict the outcome (over...
BACKGROUND: Individually tailored cancer treatment is essential to ensure optimal treatment and reso...
BACKGROUND: Individually tailored cancer treatment is essential to ensure optimal treatment and reso...
Abstract Background The current TNM staging system is far from perfect in predicting the survival of...
OBJECTIVE:Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is h...
PURPOSE: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according to the...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
PurposeAlthough patients with stage III non-small cell lung cancer (NSCLC) are homogeneous according...
Importance: Nomogram prognostic models can facilitate cancer patient treatment plans and patient enr...
The 1997 International staging system (ISS) classification separated stage III non-small cell lung c...
Purpose: Tools for survival prediction for non-small cell lung cancer (NSCLC) patients treated with ...
We sought to develop and validate a clinical nomogram model for predicting overall survival (OS) in ...
IntroductionAccurate prognosis assessment after non–small-cell lung cancer (NSCLC) diagnosis is an e...
Objective Surgery is the first choice of treatment for localised non small cell lung cancer (NSCLC) ...
Background: A clinical decision support system (CDSS) has been designed to predict the outcome (over...
BACKGROUND: Individually tailored cancer treatment is essential to ensure optimal treatment and reso...
BACKGROUND: Individually tailored cancer treatment is essential to ensure optimal treatment and reso...
Abstract Background The current TNM staging system is far from perfect in predicting the survival of...
OBJECTIVE:Overall survival (OS) for advanced stage (IIIA-IV) non-small cell lung cancer (NSCLC) is h...